Turnaround: AstraZeneca

For Pascal Soriot, less is more. He’s shed development drugs he sees little chance of becoming viable, relentlessly focussed on oncology and bio pharmaceuticals to replenish the company’s drugs pipeline while throwing AstraZeneca’s doors open to encourage collaboration. Soriot takes us through his turnaround plan and the key to pushing through cultural change.

Genre: Business
Duration: 00:24:06
For all licensing enquiries and screeners, please contact us at: info@atallorder.co.uk

This website contains material which is owned by or licensed to us. This material includes, but is not limited to, the design, layout, look, appearance and graphics. Reproduction is prohibited other than in accordance with the copyright notice, which forms part of these terms and conditions. Our full terms and conditions can be read online here.